MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Scheerens, Heleen ^a   Su, Zheng ^a   Irving, Bryan ^a   Townsend, Michael J ^a   Zheng, Yanan ^a   Stefanich, Eric ^a   Chindalore, Vishala ^b   Bingham III, Clifton O ^c   Davis Jr, John C ^a  

^a GENENTECH INC   (United States)

^b Pinnacle Research Center Anniston Medical Clinic PC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antibody; Pharmacodynamics; Phase i; Rheumatoid arthritis

Indexed keywords

BIOLOGICAL MARKER; CD4 ANTIBODY; HUMAN MONOCLONAL ANTIBODY; MTRX1011A; UNCLASSIFIED DRUG; CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PAPULAR RASH; PHASE 1 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOWN REGULATION; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; HUMANS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 83355174221     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3502     Document Type: Article

References (27)

1. Criscione LG, St Clair EW. Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002, 14:204-211. 10.1097/00002281-200205000-00002, 11981314.
2. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 2007, 46:1153-1156. Oxford, 10.1093/rheumatology/kem075, 17478470.
3. Pitzalis C, Kingsley G, Murphy J, Panayi G. Abnormal distribution of the helper-inducer and suppressor-inducer T-lymphocyte subsets in the rheumatoid joint. Clin Immunol Immunopathol 1987, 45:252-258. 10.1016/0090-1229(87)90040-7, 2959423.
4. Pitzalis C, Kingsley GH, Covelli M, Meliconi R, Markey A, Panayi GS. Selective migration of the human helper-inducer memory T cell subset: confirmation by in vivo cellular kinetic studies. Eur J Immunol 1991, 21:369-376. 10.1002/eji.1830210218, 1671837.
5. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 1981, 2:839-842.
6. Fugger L, Svejgaard A. Association of MHC and rheumatoid arthritis. HLA-DR4 and rheumatoid arthritis: studies in mice and men. Arthritis Res 2000, 2:208-211. 10.1186/ar89, 130004, 11094431.
7. Chu CQ, Londei M. Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J Immunol 1996, 157:2685-2689.
8. Choy EH. Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:510-518.
9. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006, 23:95-103. 10.1007/s11095-005-8814-3, 16308668.
10. Burton DR, Dwek RA. Immunology. Sugar determines antibody activity. Science 2006, 313:627-628. 10.1126/science.1131712, 16888131.
11. Chao DT, Ma X, Li O, Park H, Law D. Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies. Immunol Invest 2009, 38:76-92. 10.1080/08820130802608238, 2646398, 19172487.
12. Isaacs JD, Clark MR, Greenwood J, Waldmann H. Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. J Immunol 1992, 148:3062-3071.
13. Lund J, Pound JD, Jones PT, Duncan AR, Bentley T, Goodall M, Levine BA, Jefferis R, Winter G. Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11. Mol Immunol 1992, 29:53-59. 10.1016/0161-5890(92)90156-R, 1530984.
14. Zheng Y, Scheerens H, Davis JC, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase i study. Clin Pharmacol Ther 2011, 89:283-290. 10.1038/clpt.2010.311, 21191378.
15. Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 2002, 29:220-229.
16. Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, Kraan MC, Kalden JR, Rascu A, Brown JC, Rapson N, Johnston JM. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology 2002, 41:1142-1148. Oxford, 10.1093/rheumatology/41.10.1142, 12364634.
17. Luggen ME, Schechtman J, Kivitz A. Results of a phase II, double-blind, randomized study of a nondepeting anti-CD4 monoclonal antibody (clenoliximab) given in combination with methotrexate (MTX) in patients with moderate to severe rheumatoid arthritis. Annual European Congress of Rheumatology 2003, Lisbon, Portugal.
18. Moreland LW, Pratt PW, Bucy RP, Jackson BS, Feldman JW, Koopman WJ. Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody. Long-term followup of CD4+ T cell counts. Arthritis Rheum 1994, 37:834-838. 10.1002/art.1780370610, 7911664.
19. van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995, 38:1097-1106. 10.1002/art.1780380812, 7639806.
20. Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, Panayi GS, Johnston JM. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology 2000, 39:1139-1146. Oxford, 10.1093/rheumatology/39.10.1139, 11035136.
21. Choy EH, Pitzalis C, Cauli A, Bijl JA, Schantz A, Woody J, Kingsley GH, Panayi GS. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum 1996, 39:52-56. 10.1002/art.1780390107, 8546738.
22. Rep MH, van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest 1997, 99:2225-2231. 10.1172/JCI119396, 508053, 9151795.
23. Symons JA, McCulloch JF, Wood NC, Duff GW. Soluble CD4 in patients with rheumatoid arthritis and osteoarthritis. Clin Immunol Immunopathol 1991, 60:72-82. 10.1016/0090-1229(91)90113-O, 1904330.
24. Verneuil L, Dompmartin A, Comoz F, Pasquier CJ, Leroy D. Interstitial granulomatous dermatitis with cutaneous cords and arthritis: a disorder associated with autoantibodies. J Am Acad Dermatol 2001, 45:286-291. 10.1067/mjd.2001.114577, 11464193.
25. Sangueza OP, Caudell MD, Mengesha YM, Davis LS, Barnes CJ, Griffin JE, Fleischer AB, Jorizzo JL. Palisaded neutrophilic granulomatous dermatitis in rheumatoid arthritis. J Am Acad Dermatol 2002, 47:251-257. 10.1067/mjd.2002.124620, 12140472.
26. Chu P, Connolly MK, LeBoit PE. The histopathologic spectrum of palisaded neutrophilic and granulomatous dermatitis in patients with collagen vascular disease. Arch Dermatol 1994, 130:1278-1283. 10.1001/archderm.130.10.1278, 7944509.
27. Kim SK, Park CK, Park YW, Jun JB, Yoo DH, Bae SC. Palisaded neutrophilic granulomatous dermatitis presenting as an unusual skin manifestation in a patient with Behcet's disease. Scand J Rheumatol 2005, 34:324-327. 10.1080/03009740510015195, 16195168.